-
1.发明授权Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases 失效使用IL-12和IL-12拮抗剂治疗自身免疫性疾病公开(公告)号：US08231874B2
公开(公告)日：2012-07-31
申请号：US13192920
申请日：2011-07-28
CPC分类号： A61K39/3955 , A61K38/208 , A61K2039/505 , C07K16/244 , C07K16/249 , C07K2317/76 , Y10S514/825 , Y10S514/866 , Y10S514/903
摘要： Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-γ or TNF-α. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
摘要翻译： 公开了治疗自身免疫病症的方法，其包括向哺乳动物受试者IL-12或IL-12拮抗剂施用。 在某些优选实施方案中，自身免疫病症是通过IFN-γ或TNF-α水平升高而促进的。 合适的治疗条件包括多发性硬化，系统性红斑狼疮，类风湿性关节炎，自身免疫性肺部炎症，吉兰巴利综合征，自身免疫性甲状腺炎，胰岛素依赖型糖尿病，自身免疫性炎症性眼病。
-
2.发明授权Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases 失效使用IL-12和IL-12拮抗剂治疗自身免疫性疾病公开(公告)号：US08012475B2
公开(公告)日：2011-09-06
申请号：US12453564
申请日：2009-05-14
CPC分类号： A61K39/3955 , A61K38/208 , A61K2039/505 , C07K16/244 , C07K16/249 , C07K2317/76 , Y10S514/825 , Y10S514/866 , Y10S514/903
摘要： Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-γ or TNF-α. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
摘要翻译： 公开了治疗自身免疫病症的方法，其包括向哺乳动物受试者IL-12或IL-12拮抗剂施用。 在某些优选实施方案中，自身免疫病症是通过IFN-γ或TNF-α水平升高而促进的。 合适的治疗条件包括多发性硬化，系统性红斑狼疮，类风湿性关节炎，自身免疫性肺部炎症，吉兰巴利综合征，自身免疫性甲状腺炎，胰岛素依赖型糖尿病，自身免疫性炎症性眼病。
-
3.发明申请Use of IL-12 and IL-12 Antagonists in the Treatment of Autoimmune Diseases 审中-公开使用IL-12和IL-12拮抗剂治疗自身免疫性疾病公开(公告)号：US20130089515A1
公开(公告)日：2013-04-11
申请号：US13563009
申请日：2012-07-31
IPC分类号： A61K39/395 , A61K38/20
CPC分类号： A61K39/3955 , A61K38/208 , A61K2039/505 , C07K16/244 , C07K16/249 , C07K2317/76 , Y10S514/825 , Y10S514/866 , Y10S514/903
摘要： Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-γ or TNF-α. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
摘要翻译： 公开了治疗自身免疫病症的方法，其包括向哺乳动物受试者IL-12或IL-12拮抗剂施用。 在某些优选实施方案中，自身免疫病症是通过IFN-γ或TNF-α水平升高而促进的。 合适的治疗条件包括多发性硬化，系统性红斑狼疮，类风湿性关节炎，自身免疫性肺部炎症，吉兰巴利综合征，自身免疫性甲状腺炎，胰岛素依赖型糖尿病，自身免疫性炎症性眼病。
-
公开(公告)号：US07534430B2
公开(公告)日：2009-05-19
申请号：US11528584
申请日：2006-09-28
CPC分类号： A61K39/3955 , A61K38/208 , A61K2039/505 , C07K16/244 , C07K16/249 , C07K2317/76 , Y10S514/825 , Y10S514/866 , Y10S514/903
摘要： Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-γ or TNF-α. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
-
5.发明授权Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y 失效使用IL-12拮抗剂治疗由IFN-γ水平升高促进的病症公开(公告)号：US06706264B1
公开(公告)日：2004-03-16
申请号：US09512930
申请日：2000-02-25
IPC分类号： A61K39395
CPC分类号： A61K39/3955 , A61K38/208 , A61K2039/505 , C07K16/244 , C07K16/249 , C07K2317/76 , Y10S514/825 , Y10S514/866 , Y10S514/903
摘要： Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-&ggr; or TNF-&agr;. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
摘要翻译： 公开了治疗自身免疫病症的方法，其包括向哺乳动物受试者IL-12或IL-12拮抗剂施用。 在某些优选的实施方案中，自身免疫病症是通过IFN-γ或TNF-α水平升高而促进的。 合适的治疗条件包括多发性硬化，系统性红斑狼疮，类风湿性关节炎，自身免疫性肺部炎症，吉兰巴利综合征，自身免疫性甲状腺炎，胰岛素依赖型糖尿病，自身免疫性炎症性眼病。
-
6.发明申请USE OF IL-12 AND IL-12 ANTAGONISTS IN THE TREATMENT OF AUTOIMMUNE DISEASES 失效IL-12和IL-12拮抗剂在治疗自身免疫性疾病中的应用公开(公告)号：US20120020916A1
公开(公告)日：2012-01-26
申请号：US13192920
申请日：2011-07-28
CPC分类号： A61K39/3955 , A61K38/208 , A61K2039/505 , C07K16/244 , C07K16/249 , C07K2317/76 , Y10S514/825 , Y10S514/866 , Y10S514/903
摘要： Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-γ or TNF-α. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
摘要翻译： 公开了治疗自身免疫病症的方法，其包括向哺乳动物受试者IL-12或IL-12拮抗剂施用。 在某些优选实施方案中，自身免疫病症是通过IFN-γ或TNF-α水平升高而促进的。 合适的治疗条件包括多发性硬化，系统性红斑狼疮，类风湿性关节炎，自身免疫性肺部炎症，吉兰巴利综合征，自身免疫性甲状腺炎，胰岛素依赖型糖尿病，自身免疫性炎症性眼病。
-
7.发明授权Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases 有权使用IL-12和IL-12拮抗剂治疗自身免疫性疾病公开(公告)号：US06338848B1
公开(公告)日：2002-01-15
申请号：US09513380
申请日：2000-02-25
IPC分类号： A61K39395
CPC分类号： A61K38/208 , A61K2039/505 , C07K16/244
摘要： Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-&ggr; or TNF-&agr;. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
摘要翻译： 公开了治疗自身免疫病症的方法，其包括向哺乳动物受试者IL-12或IL-12拮抗剂施用。 在某些优选的实施方案中，自身免疫病症是通过IFN-γ或TNF-α水平的升高而促进的。 合适的治疗条件包括多发性硬化，系统性红斑狼疮，类风湿性关节炎，自身免疫性肺部炎症，吉兰巴利综合征，自身免疫性甲状腺炎，胰岛素依赖型糖尿病，自身免疫性炎症性眼病。
-
公开(公告)号：US20090263351A1
公开(公告)日：2009-10-22
申请号：US12453564
申请日：2009-05-14
IPC分类号： A61K38/20 , A61K39/395 , A61P37/02
CPC分类号： A61K39/3955 , A61K38/208 , A61K2039/505 , C07K16/244 , C07K16/249 , C07K2317/76 , Y10S514/825 , Y10S514/866 , Y10S514/903
摘要： Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-γ or TNF-α. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
-
公开(公告)号：US07138115B2
公开(公告)日：2006-11-21
申请号：US10659586
申请日：2003-09-11
CPC分类号： A61K39/3955 , A61K38/208 , A61K2039/505 , C07K16/244 , C07K16/249 , C07K2317/76 , Y10S514/825 , Y10S514/866 , Y10S514/903
摘要： Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-γ or TNF-α. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
-
公开(公告)号：US06830751B1
公开(公告)日：2004-12-14
申请号：US09512701
申请日：2000-02-25
IPC分类号： A61K39395
CPC分类号： A61K39/3955 , A61K38/208 , A61K2039/505 , C07K16/244 , C07K16/249 , C07K2317/76 , Y10S514/825 , Y10S514/866 , Y10S514/903
摘要： Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-&ggr; or TNF-&agr;. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
摘要翻译： 公开了治疗自身免疫病症的方法，其包括向哺乳动物受试者IL-12或IL-12拮抗剂施用。 在某些优选的实施方案中，自身免疫病症是通过IFN-γ或TNF-α水平升高而促进的。 合适的治疗条件包括多发性硬化，系统性红斑狼疮，类风湿性关节炎，自身免疫性肺部炎症，吉兰巴利综合征，自身免疫性甲状腺炎，胰岛素依赖型糖尿病，自身免疫性炎症性眼病。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.012 秒)
